Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMA-638 · 2 trials · 1 indication
The PEFR is a participant's maximum speed of expiration, as measured with a peak flow meter. All participants were issued with the peak flow meter and instructed to perform the activity in triplicate in the morning prior to taking bronchodilator. The best among the 3 readings was selected.
The PEFR is a participant's maximum speed of expiration, as measured with a peak flow meter. All participants were issued with the peak flow meter and instructed to perform the activity in triplicate in the morning prior to taking bronchodilator. The best among the 3 readings was selected.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| IMA-638 | BIOLOGICAL | SC Injection, 12 weeks |
| placebo | OTHER | placebo |
Inclusion Criteria: * Generally healthy men and women with persistent asthma, 18 to 70 years of age, with body weight between 50 kg and 115 kg. * History of treatment with a medium to high dose of inhaled corticosteroids (ICS), with or without long-acting beta-agonists (LABA), for at least 2 months...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
IMA-638 is an investigational small molecule developed for the treatment of asthma, a respiratory condition. It was studied in adults with persistent asthma. Both of its clinical trials have been completed, and it is not currently listed as an active development program.
IMA-638 is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer sponsored the clinical studies of the drug in asthma, including a Phase 2 trial and a Phase 1 trial conducted in the United States and Canada.
IMA-638 reached Phase 2 clinical development for asthma. Two trials have been completed: a Phase 2 study and a Phase 1 study. No trials are currently active, and the drug is investigational rather than approved.
IMA-638 has been studied in two completed trials. NCT00425061 was a Phase 2 study evaluating the effect of IMA-638 in subjects with persistent asthma, enrolling 159 participants in the United States and Canada. NCT00339872 was a Phase 1 study of IMA-638 in asthma conducted in the United States.
The IMA-638 trials in asthma were randomized, double-blind, and placebo-controlled, enrolling adults 18 years and older. The Phase 2 trial NCT00425061 enrolled 159 participants across the United States and Canada. Neither trial selected patients based on a biomarker.